Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke Statistics—2023 update: A report from the American heart association. Circulation. 2023;147(8):e93–621.

PubMed Central  PubMed  Google Scholar 

Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The heart of the world. Glob Heart. 2024;19(1):11.

PubMed Central  PubMed  Google Scholar 

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic health: A presidential advisory from the American heart association. Circulation. 2023;148(20):1606–35.

PubMed  Google Scholar 

Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic syndrome stages in US adults, 2011–2020. JAMA. 2024;331(21):1858–60.

CAS  PubMed Central  PubMed  Google Scholar 

Zhu R, Wang R, He J, Wang L, Chen H, Niu X, et al. Prevalence of Cardiovascular-Kidney-Metabolic syndrome stages by social determinants of health. JAMA Netw Open. 2024;7(11):e2445309–e.

PubMed Central  PubMed  Google Scholar 

Chalasani R, Krishnamurthy S, Suda KJ, Newman TV, Delaney SW, Essien UR. Pursuing pharmacoequity: determinants, drivers, and pathways to progress. J Health Polit Policy Law. 2022;47(6):709–29.

PubMed  Google Scholar 

Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: A scientific statement from the American heart association. Circulation. 2023;148(20):1636–64.

PubMed  Google Scholar 

April-Sanders AK. Integrating social determinants of health in the management of Cardiovascular‐Kidney‐Metabolic syndrome. J Am Heart Association. 2024;13(16):e036518.

Google Scholar 

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.

CAS  PubMed Central  PubMed  Google Scholar 

Dorans KS, Mills KT, Liu Y, He J. Trends in prevalence and control of hypertension according to the 2017 American college of cardiology/american heart association (ACC/AHA) guideline. J Am Heart Association. 2018;7(11):e008888.

Google Scholar 

Abrahamowicz AA, Ebinger J, Whelton SP, Commodore-Mensah Y, Yang E. Racial and ethnic disparities in hypertension: barriers and opportunities to improve blood pressure control. Curr Cardiol Rep. 2023;25(1):17–27.

PubMed Central  PubMed  Google Scholar 

Ferdinand KC, Yadav K, Nasser SA, Clayton-Jeter HD, Lewin J, Cryer DR, et al. Disparities in hypertension and cardiovascular disease in blacks: the critical role of medication adherence. J Clin Hypertens (Greenwich). 2017;19(10):1015–24.

PubMed  Google Scholar 

Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC, Race. Ethnicity, hypertension, and heart disease: JACC focus seminar 1/9. J Am Coll Cardiol. 2021;78(24):2460–70.

PubMed  Google Scholar 

Aggarwal R, Chiu N, Wadhera RK, Moran AE, Raber I, Shen C, et al. Racial/Ethnic disparities in hypertension prevalence, awareness, treatment, and control in the united states, 2013 to 2018. Hypertension. 2021;78(6):1719–26.

CAS  PubMed  Google Scholar 

Hayes DK, Jackson SL, Li Y, Wozniak G, Tsipas S, Hong Y, et al. Blood pressure control among Non-Hispanic black adults is lower than Non-Hispanic white adults despite similar treatment with antihypertensive medication: NHANES 2013–2018. Am J Hypertens. 2022;35(6):514–25.

PubMed Central  PubMed  Google Scholar 

Essien UR, Corbie G. Getting under the skin: Race-Based guidelines and the pursuit of pharmacoequity. J Gen Intern Med. 2022;37(16):4035–6.

PubMed Central  PubMed  Google Scholar 

Flack JM, Bitner S, Buhnerkempe M. Evolving the role of black race in hypertension therapeutics. Am J Hypertens. 2024;37(10):739–44.

CAS  PubMed  Google Scholar 

Holt HK, Gildengorin G, Karliner L, Fontil V, Pramanik R, Potter MB. Differences in hypertension medication prescribing for black Americans and their association with hypertension outcomes. J Am Board Family Med. 2022;35(1):26–34.

Google Scholar 

Rabay CJ, Lopez C, Streuli S, Mayes EC, Rajagopalan RM, Non AL. Clinicians’ perspectives on race-specific guidelines for hypertensive treatment. Soc Sci Med. 2024;351:116938.

PubMed  Google Scholar 

Savage LC, Panofsky A. The Self-Fulfilling process of clinical race correction: the case of eighth joint National committee recommendations. Health Equity. 2023;7(1):793–802.

PubMed Central  PubMed  Google Scholar 

Egan BM, Yang J, Rakotz MK, Sutherland SE, Jamerson KA, Wright JT, et al. Self-Reported antihypertensive medication class and Temporal relationship to treatment guidelines. Hypertension. 2022;79(2):338–48.

CAS  PubMed  Google Scholar 

Anderson TS, Ayanian JZ, Zaslavsky AM, Souza J, Landon BE. National trends in antihypertensive treatment among older adults by race and presence of comorbidity, 2008 to 2017. J Gen Intern Med. 2022;37(16):4223–32.

PubMed Central  PubMed  Google Scholar 

Chu CD, Powe NR, McCulloch CE, Banerjee T, Crews DC, Saran R, et al. Angiotensin-Converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with albuminuria. Hypertension. 2021;77(1):94–102.

CAS  PubMed  Google Scholar 

Gu A, Farzadeh SN, Chang YJ, Kwong A, Lam S. Patterns of antihypertensive drug utilization among US adults with diabetes and comorbid hypertension: the National health and nutrition examination survey 1999–2014. Clin Med Insights: Cardiol. 2019;13:1179546819839418.

PubMed  Google Scholar 

Shen L, Lee MMY, Jhund PS, Granger CB, Anand IS, Maggioni AP, et al. Revisiting race and the benefit of RAS Blockade in heart failure: A Meta-Analysis of randomized clinical trials. JAMA. 2024;331(24):2094–104.

CAS  PubMed Central  PubMed  Google Scholar 

Limonte CP, Lamprea-Montealegre JA, Tuttle KR. Challenges and strategies in implementing novel kidney protective and cardioprotective therapies in patients with diabetes and kidney disease. Semin Nephrol. 2024;44(2):151520.

CAS  PubMed Central  PubMed  Google Scholar 

Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3298–309.

PubMed Central  PubMed  Google Scholar 

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148–58.

PubMed  Google Scholar 

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–54.

CAS  PubMed  Google Scholar 

Usman Muhammad S, Siddiqi Tariq J, Anker Stefan D, Bakris George L, Bhatt Deepak L, Filippatos G, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377–87.

PubMed  Google Scholar 

Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, et al. Sodium-Glucose Cotransporter-2 inhibitors and major adverse cardiovascular outcomes: A SMART-C collaborative Meta-Analysis. Circulation. 2024;149(23):1789–801.

CAS  PubMed Central  PubMed  Google Scholar 

Limonte CP, Hall YN, Trikudanathan S, Tuttle KR, Hirsch IB, de Boer IH, et al. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabetes Complicat. 2022;36(6):108204.

CAS  Google Scholar 

Nicholas SB, Daratha KB, Alicic RZ, Jones CR, Kornowske LM, Neumiller JJ et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019–2020. Diabetes, Obesity and Metabolism. 2023;25(10):2970-9.

Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. J Am Heart Association. 2021;10(13):e021084.

CAS  Google Scholar 

Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, et al. Association of race/ethnicity, gender, and socioeconomic status with Sodium-Glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021;4(4):e216139.

PubMed Central  PubMed  Google Scholar 

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21.

CAS  PubMed  Google Scholar 

Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J, et al. Racial, ethnic, and socioeconomic inequities in Glucagon-Like Peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum. 2021;2(12):e214182.

PubMed Central  PubMed  Google Scholar 

Zhao JZ, Weinhandl ED, Carlson AM, St Peter WL. Hypoglycemia risk with SGLT2 inhibitors or Glucagon-Like peptide 1 receptor agonists versus sulfonylureas among medicare insured adults with CKD in the united States. Kidney Med. 2022;4(8):100510.

PubMed Central  PubMed  Google Scholar 

Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR® research to practice project. Eur J Prev Cardiol. 2020;24(15):1637–45.

Google Scholar 

Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2